<DOC>
	<DOCNO>NCT00561496</DOCNO>
	<brief_summary>This multi-center , pharmacokinetic study involve single-dose phase , wash phase two-week twice-daily dosing phase 49 volunteer . In single-dose phase , volunteer apply single dose clinic . Participants randomize cervicovaginal sample biopsy collect one seven time-points [ 0.5 , 1 , 2 , 4 , 6 , 8 , 24 hour ( ) ] single-dose . Blood sample draw 0.5 , 1 , 2 , 4 , 6 , 8 , 24 hour ( ) single-dose . In two-week phase , study supply distribute participant randomize apply dose either twice-daily two week . At one week follow-up visit blood sample drawn prior morning dose obtain trough value cervicovaginal sample collect four hour morning dose . At two week follow-up visit blood sample draw prior morning dose obtain trough value 0.5 , 1 , 2 , 4 , 6 , 8 , 24 hour ( ) final morning dose . Participants randomize cervicovaginal sample biopsy collect either 4 , 8 24 hour final morning dose . Up 10 participant complete first two phase study , ask participate third phase cervicovaginal sample , biopsy blood sample collect 12 hour single-dose .</brief_summary>
	<brief_title>Pharmacokinetic Study Vaginal Microbicide Agent 1 % Tenofovir Gel</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Must 1845 year old , inclusive Must general good health volunteer history without clinically significant systemic disease ( include liver disease/hepatitis , gastrointestinal disease , kidney disease , thyroid disease , osteoporosis bone disease ) Must regular menstrual cycle ( minimum 26 maximum 38 day ) Must least 2 month since last pregnancy outcome least two spontaneous menses Must abstain sexual activity use intravaginal product 72 hour prior start singledose phase multidose phase , least one week follow vaginal biopsy duration study phase Willingness give voluntary consent , sign inform consent form comply study procedure require protocol Currently pregnant risk pregnancy ( may use Paragard® IUD , effective barrier method , female sterilization abstinence , sexually active vasectomized partner ) Currently breastfeed plan breastfeed course study Use hormonal contraceptive within 30 day enrollment Use DepoProvera within 120 day enrollment History abnormal Pap smear ( volunteer history ) evaluate treat , indicate , accord standard guideline Current vaginal urinary tract infection Positive test Neisseria gonorrhea Chlamydia trachomatis time screen Positive wet mount Trichomonas vaginalis time screen enrollment Deep epithelial genital finding abrasion , ulceration , laceration , vesicle suspicious sexually transmit infection Current past use antiretroviral therapy include limited systemic tenofovir ( Viread® ) Current recent drug alcohol abuse Current anticipate use drug daily basis may reduce renal function ( e.g . acyclovir ibuprofen ) liver function ( e.g . tylenol ) HIV positive time screen Hepatitis B surface antigen ( HBsAg ) positive time screen Grade 1 high serum chemistry complete blood count abnormality accordance DAIDS toxicity table value Abnormal find laboratory physical examination medical condition , opinion investigator , would make participation study unsafe would complicate interpretation data Participation research study 30 day prior screen and/or plan participate research study entire study duration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>HIV prevention</keyword>
	<keyword>Microbicides</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>vaginal biopsy</keyword>
</DOC>